2012 Fiscal Year Final Research Report
Characterization of drug penetration to the brain for preventing development of symptoms and progress of the aging disease
| Project/Area Number |
22590149
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
FUKAMI Toshiro 日本大学, 薬学部, 准教授 (20366628)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | アルツハイマー病 / パーキンソン病 / 脳内移行性 / アンチエイジング |
|---|
| Research Abstract |
This study characterized penetration of several drugs to the brain for preventing development of symptoms and progress of the aging disease. (1) Curcumin permeation into bovine brain microvascular endothelial cells could not determine with limitation of detection in HPLC-UV method. (2) Transport of [3^H]fluvastatin into bovine brain microvascular endothelial cells was involved in the carrier-mediated mechanism. (3) Transport of [3^H]amantadine into rat brain microvascular endothelial cells was involved in the organic cation-sensitive transport system. About 50% of amantadine decreased comparatively slowly in 60 minutes after the microinject in a rat cerebrum. (4) It was suggested that the transporter intervention transport efficiency of levodopa decreases slightly in Parkinson's disease. (5) Participation of a simple diffusion mechanism and P-glycoprotein in the transport of mazindol at the blood-brain barrier, and (6) no influences of P-glycoprotein at the blood-brain barrier transport of amantadine, were demonstrated from experiments using human brain microvascular endothelium cells or the brain perfusion technique. (7) Serum creatinine (SCr) increased significantly following sulfamethoxazole-trimethoprim (SMX-TMP) combination product use in patients ?74 years of age and ?75 years of age, in both males and females, and in patients with a total dose of ?8 g (8 to 96 g) (P<0.05). The group with a total dose of ?8 g (mean 29.8 g) had a significant SCr increase of 18.4% (P=0.002), while the increase in the ?7 g (mean 5.3 g) group was only 4.5%. The data showed that SCr increased byabout 20% when the total dose taken over the treatment period was around 30 g (about2.4 g as TMP) and indicated that total dose contributes more than age and sex to the post-treatment increase in SCr.
|
-
-
-
-
-
-
-
-
[Book] Brain Edema XV2013
Author(s)
Toyofumi Suzuki, Yumiko Miyazaki, Aya Ohmuro, Masaki Watanabe, Takayuki Furuishi, Toshiro Fukami, Kazuo Tomono, Springer, Brain Edema XV(Acta Neurochirurgica Supplement 118)
Total Pages
297-302
-
-
